Among the 11 proteins commonly dysregulated in dormant cells from both pathologies (Table 1), public data analysis from AML patient cohorts [22, 23] (n = 905) revealed that four of them—SELENBP1, SEPTIN9, GYG, and ENO1—demonstrated significantly greater expression in patients with adverse prognoses (ELN 2017 classification). Here, SELENBP1 is linked to acute myeloid leukemia.